June 21, 2024
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, N. E.
Washington, D.C. 20549
Ladies and Gentlemen:
We have read the comments made regarding us in Item 4.01 of Form 8-K of Eton Pharmaceuticals, Inc. dated June 14, 2024, and are in agreement with those statements.
/s/ KMJ Corbin & Company LLP
Irvine, California
Attachments
- Original Link
- Permalink
Disclaimer
Eton Pharmaceuticals Inc. published this content on 21 June 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 June 2024 20:18:33 UTC.